ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Barclays Sweeps Energy and Chemicals on Friday

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Barclays dominated Friday's analyst tape, issuing a sweep of target price revisions across energy, chemicals, and consumer sectors.

The sharpest cut came on ALB. Barclays analyst Aleksey Yefremov trimmed the target on Albemarle to $95 from $109. The lithium producer already sits in a majority-sell consensus, with 14 of 23 analysts recommending investors sell.

DVN also took a hit. Betty Jiang at Barclays cut the Devon Energy target to $57 from $60, keeping a Buy rating. That Buy rating is unusual: the full consensus on Devon is 28 sells, zero buys from other analysts, making Barclays one of the most bullish voices on the name.

APD saw its target trimmed to $346 from $353. Barclays held its Buy rating on Air Products, though the consensus leans bearish with 15 sells against eight holds.

The biggest upward target move came on ABNB. Ross Sandler raised his Airbnb target to $195 from $150, a 30% jump, while holding a neutral stance. Despite that large move, 25 of 44 analysts remain sellers on the stock.

ED drew dual upgrades. Both Barclays and Wells Fargo lifted targets on Consolidated Edison. Wells Fargo's Shahriar Pourreza went furthest, raising the target to $134 from $118 with a Buy rating.

MCHP faced the most bearish shift in semiconductors. B. Riley Securities cut the Microchip Technology target to $85 from $98, against a backdrop of 20 sell ratings and zero buys from the broader analyst community.

Stocks in this article

How this article was generated

Generated
6 Nov 2026, 16:21
Prompt version
v1.0
Data sources
Analyst consensusAlt DataIndex Rebalance

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.